$PVLA News

Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel

Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands

Palvella (PVLA) Q2 2026 Earnings Call Transcript

Is Palvella Therapeutics (PVLA) Fully Valued Ahead Of QTORIN Approval?

Palvella Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Palvella Therapeutics Inc (PVLA) (Q2 2026) Earnings Call Highlights: Strong Phase 3 Data and ...

Palvella Therapeutics Q2 Earnings Call Highlights

Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript

Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call

Palvella Therapeutics Q2 EPS $(1.52) Misses $(1.14) Estimate

Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing

Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026

Palvella Therapeutics (PVLA) Submits Initial Module of NDA For QTORIN

Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Palvella Therapeutics Submits First Module Of Rolling NDA To FDA Seeking Approval Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic Malformations

What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally

Palvella Shares Advance After FDA Grants Rolling Review for Rare Disease Therapy

FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations